Last reviewed · How we verify

NCT06235424

Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement

Status unknown Phase 4 Last updated 31 January 2024
What this trial tests

Phase 4 trial testing Del Nido Cardioplegia Solution in Aortic Valve Disease in 100 participants. Status unknown.

Timeline
1 October 2018
Primary endpoint
24 April 2023
24 September 2024

Quick facts

Lead sponsorMedical University of Gdansk
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 October 2018
Primary completion24 April 2023
Estimated completion24 September 2024
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Gdansk

Who can join

18 and older, any sex, with Aortic Valve Disease or Valve Disease, Heart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare del Nido and Bretschneider-HTK (HTK) cardioplegia solutions in patients undergoing elective aortic valve replacement. The main question it aims to answer is: • Does the del Nido cardioplegia provide better cardioprotection and clinical outcomes than HTK cardioplegia? Participants will receive one of the investigated cardioplegia solutions according to the randomization. Researchers will compare both groups in terms of cardioprotection (described as levels of CK-MB and hsTnI), in-hospital clinical outcomes, biochemical changes in coronary sinus blood and one-year follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Valve Disease

Currently open trials in the same condition.

Other Medical University of Gdansk trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06235424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing